|
1.
|
Li C, Thompson MA, Tamayo AT, et al:
Over-expression of Thioredoxin-1 mediates growth, survival, and
chemoresistance and is a druggable target in diffuse large B-cell
lymphoma. Oncotarget. 3:314–326. 2012.PubMed/NCBI
|
|
2.
|
Yang J, Li C, Ding L, Guo Q, You Q and Jin
S: Gambogic acid deactivates cytosolic and mitochondrial
thioredoxins by covalent binding to the functional domain. J Nat
Prod. 75:1108–1116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Chae JS, Gil Hwang S, Lim DS and Choi EJ:
Thioredoxin-1 functions as a molecular switch regulating the
oxidative stress-induced activation of MST1. Free Radic Biol Med.
53:2335–2343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Ungerstedt J, Du Y, Zhang H, Nair D and
Holmgren A: In vivo redox state of human thioredoxin and redox
shift by the histone deacetylase inhibitor suberoylanilide
hydroxamic acid (SAHA). Free Radic Biol Med. 53:2002–2007. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Lim JY, Yoon SO, Hong SW, Kim JW, Choi SH
and Cho JY: Thioredoxin and thioredoxin-interacting protein as
prognostic markers for gastric cancer recurrence. World J
Gastroenterol. 18:5581–5588. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Pramanik KC and Srivastava SK: Apoptosis
signal-regulating kinase 1-thioredoxin complex dissociation by
capsaicin causes pancreatic tumor growth suppression by inducing
apoptosis. Antioxid Redox Signal. 17:1417–1432. 2012. View Article : Google Scholar
|
|
7.
|
Dunn LL, Buckle AM, Cooke JP and Ng MK:
The emerging role of the thioredoxin system in angiogenesis.
Arterioscler Thromb Vasc Biol. 30:2089–2098. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Cha MK, Suh KH and Kim IH: Overexpression
of peroxiredoxin I and thioredoxin 1 in human breast carcinoma. J
Exp Clin Cancer Res. 28:932009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wondrak GT: Redox-directed cancer
therapeutics: molecular mechanisms and opportunities. Antioxid
Redox Signal. 11:3013–3069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Welsh SJ, Williams RR, Birmingham A,
Newman DJ, Kirkpatrick DL and Powis G: The thioredoxin redox
inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin
inhibit hypoxia-induced factor 1alpha and vascular endothelial
growth factor formation. Mol Cancer Ther. 2:235–243. 2003.
|
|
11.
|
Mukherjee A and Martin SG: The thioredoxin
system: a key target in tumour and endothelial cells. Br J Radiol.
81(Spec1): S57–S68. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Baker AF, Adab KN, Raghunand N, et al: A
phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1
inhibitor, in patients with advanced gastrointestinal cancers.
Invest New Drugs. 31:631–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ramanathan RK, Kirkpatrick DL, Belani CP,
et al: A Phase I pharmacokinetic and pharmacodynamic study of
PX-12, a novel inhibitor of thioredoxin-1, in patients with
advanced solid tumors. Clin Cancer Res. 13:2109–2114. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Petty RD, Nicolson MC, Kerr KM,
Collie-Duguid E and Murray GI: Gene expression profiling in
non-small cell lung cancer: from molecular mechanisms to clinical
application. Clin Cancer Res. 10:3237–3248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Fernandes AP, Capitanio A, Selenius M,
Brodin O, Rundlof AK and Bjornstedt M: Expression profiles of
thioredoxin family proteins in human lung cancer tissue:
correlation with proliferation and differentiation. Histopathology.
55:313–320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Wangpaichitr M, Sullivan EJ,
Theodoropoulos G, et al: The relationship of thioredoxin-1 and
cisplatin resistance: its impact on ROS and oxidative metabolism in
lung cancer cells. Mol Cancer Ther. 11:604–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Han YH, Kim SZ, Kim SH and Park WH:
Pyrogallol inhibits the growth of lung cancer Calu-6 cells via
caspase-dependent apoptosis. Chem Biol Interact. 177:107–114. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Han YH and Park WH: The effects of
N-acetyl cysteine, buthionine sulfoximine, diethyldithiocarbamate
or 3-amino-1,2,4-triazole on antimycin A-treated Calu-6 lung cells
in relation to cell growth, reactive oxygen species and
glutathione. Oncol Rep. 22:385–391. 2009.
|
|
19.
|
Han YH, Moon HJ, You BR, Kim SZ, Kim SH
and Park WH: Effects of carbonyl cyanide p-(trifluoromethoxy)
phenylhydrazone on the growth inhibition in human pulmonary
adenocarcinoma Calu-6 cells. Toxicology. 265:101–107. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
You BR and Park WH: Zebularine inhibits
the growth of HeLa cervical cancer cells via cell cycle arrest and
caspase-dependent apoptosis. Mol Biol Rep. 39:9723–9731. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Han YH, Moon HJ, You BR and Park WH: The
effect of MG132, a proteasome inhibitor on HeLa cells in relation
to cell growth, reactive oxygen species and GSH. Oncol Rep.
22:215–221. 2009.PubMed/NCBI
|
|
22.
|
Han YH, Kim SH, Kim SZ and Park WH:
Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) as an
O2(*-) generator induces apoptosis via the
depletion of intracellular GSH contents in Calu-6 cells. Lung
Cancer. 63:201–209. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Han YH and Park WH: Propyl gallate
inhibits the growth of HeLa cells via regulating intracellular GSH
level. Food Chem Toxicol. 47:2531–2538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
You BR and Park WH: Gallic acid-induced
lung cancer cell death is related to glutathione depletion as well
as reactive oxygen species increase. Toxicol In Vitro.
24:1356–1362. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Griffiths EJ: Mitochondria - potential
role in cell life and death. Cardiovasc Res. 46:24–27. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Vogt A, Tamura K, Watson S and Lazo JS:
Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell
cycle arrest without hyperphosphorylation of cyclin-dependent
kinase Cdk1. J Pharmacol Exp Ther. 294:1070–1075. 2000.PubMed/NCBI
|
|
27.
|
Yang J, Liu X, Bhalla K, et al: Prevention
of apoptosis by Bcl-2: release of cytochrome c from mitochondria
blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Martinou JC and Youle RJ: Mitochondria in
apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev
Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Lee YJ, Kim JH, Chen J and Song JJ:
Enhancement of metabolic oxidative stress-induced cytotoxicity by
the thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide is
mediated through the ASK1-SEK1-JNK1 pathway. Mol Pharmacol.
62:1409–1417. 2002. View Article : Google Scholar
|
|
30.
|
Estrela JM, Ortega A and Obrador E:
Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci.
43:143–181. 2006. View Article : Google Scholar
|
|
31.
|
You BR and Park WH: Arsenic trioxide
induces human pulmonary fibroblast cell death via increasing ROS
levels and GSH depletion. Oncol Rep. 28:749–757. 2012.PubMed/NCBI
|
